• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Cormorant Asset Management, Lp bought $19,625,601 worth of Ordinary Shares (2,152,738 units at $9.12)

    9/19/23 4:49:06 PM ET
    $AMAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AMAM alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Cormorant Asset Management, LP

    (Last) (First) (Middle)
    200 CLARENDON STREET
    52ND FLOOR

    (Street)
    BOSTON MA 02116

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Ambrx Biopharma Inc. [ AMAM ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    09/15/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Ordinary Shares 09/15/2023 P 1,401,505 A $9.0479(1) 68,714,590 I See Footnotes(2)(3)
    Ordinary Shares 09/18/2023 P 751,233 A $9.2447(1) 69,465,823 I See Footnotes(2)(4)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    Cormorant Asset Management, LP

    (Last) (First) (Middle)
    200 CLARENDON STREET
    52ND FLOOR

    (Street)
    BOSTON MA 02116

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Chen Bihua

    (Last) (First) (Middle)
    C/O CORMORANT ASSET MANAGEMENT, LP
    200 CLARENDON STREET, 52ND FLOOR

    (Street)
    BOSTON MA 02116

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Cormorant Global Healthcare Master Fund, LP

    (Last) (First) (Middle)
    200 CLARENDON STREET
    52ND FLOOR

    (Street)
    BOSTON MA 02116

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Cormorant Private Healthcare Fund III LP

    (Last) (First) (Middle)
    200 CLARENDON STREET
    52ND FLOOR

    (Street)
    BOSTON MA 02116

    (City) (State) (Zip)
    Explanation of Responses:
    1. Represents the weighted average sale price of American Depository Shares ("ADS") purchased in a series of open market transactions on the transaction date at prices ranging from $9.00 to $9.30 per ADS. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ADS purchased at each price. All of these ADS were purchased by the Master Fund (as defined below).
    2. Information reported herein relates to ordinary shares represented by ADS owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund III, LP ("Fund III"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund and Fund III. Cormorant Global Healthcare GP, LLC ("GP LLC") and Cormorant Private Healthcare GP III, LLC ("GP III") serve as General Partner of the Master Fund and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP III. Each of the Reporting Persons disclaims beneficial ownership of the ordinary shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
    3. Represents (i) 51,172,870 ordinary shares beneficially owned by the Master Fund and (ii) 17,541,720 ordinary shares beneficially owned by Fund III.
    4. Represents (i) 51,924,103 ordinary shares beneficially owned by the Master Fund and (ii) 17,541,720 ordinary shares beneficially owned by Fund III.
    /s/ CORMORANT ASSET MANAGEMENT, LP By: Cormorant Asset Management GP, LLC, its General Partner 09/19/2023
    /s/ Bihua Chen 09/19/2023
    /s/ CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP By: Cormorant Global Healthcare GP, LLC, its General Partner 09/19/2023
    /s/ CORMORANT PRIVATE HEALTHCARE FUND III LP By: Cormorant Global Healthcare GP, LLC, its General Partner By: Bihua Chen, its Manager Member 09/19/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AMAM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMAM

    DatePrice TargetRatingAnalyst
    9/25/2023$15.00Mkt Outperform
    JMP Securities
    9/12/2023$26.00Buy
    BTIG Research
    7/31/2023$29.00Outperform
    RBC Capital Mkts
    6/14/2023$26.00Buy
    B. Riley Securities
    6/2/2023$30.00Outperform
    Oppenheimer
    5/19/2023$25.00Overweight
    Cantor Fitzgerald
    4/7/2022$16.00Outperform
    Robert W. Baird
    2/28/2022$6.00Neutral
    Goldman Sachs
    More analyst ratings

    $AMAM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

      – Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry

      10/29/24 8:00:00 AM ET
      $AMAM
      $KURA
      $RNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ambrx Shareholders Approve Acquisition by Johnson & Johnson

      SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., ("Ambrx" or the "Company") (NASDAQ:AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of Shareholders. As previously announced, under the terms of the transaction, Ambrx shareholders will receive $28.00 per share in cash in connection with the closing of the transaction. Daniel J. O'Connor, Chief Executive Officer of Ambrx, said, "We want to thank our shareholders for their strong support of this transaction. With a steadfast focus on protein engineering innovation and some of the best ADC talent in t

      3/6/24 1:20:00 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Announces Sale to Johnson & Johnson

      SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ:AMAM), today announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire all of the outstanding shares of Ambrx for $28.00 per share in cash, representing an approximately 105% premium to Ambrx's closing stock price on January 5, 2024, for a total equity value of approximately $2.0 billion. "We are excited to reach this agreement with Johnson & Johnson for advancing scientific research to treat cancers with high unmet needs," said Daniel J. O'Connor, Chief Executive Officer of Ambrx. "With our deep and unique knowledge of precision engineering of protein ther

      1/8/24 7:35:00 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care